Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from RedHill Biopharma ( (RDHL) ) is now available.
On August 20, 2025, RedHill Biopharma announced that the New York Supreme Court awarded the company approximately $1.82 million in legal costs and expenses in addition to a prior summary judgment of $8.25 million against Kukbo Co. Ltd. This legal victory, which includes a 9% ongoing statutory interest accrual, strengthens RedHill’s financial position and could impact its operations positively. Additionally, RedHill secured an attachment grant from Korea’s Incheon District Court, allowing for the seizure of Kukbo’s assets, which further solidifies its legal standing. Kukbo has appealed the summary judgment decision, with oral arguments scheduled for September.
The most recent analyst rating on (RDHL) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. market. The company promotes Talicia® for treating Helicobacter pylori infection and has several late-stage clinical programs targeting conditions such as COVID-19, Crohn’s disease, and cancer.
Average Trading Volume: 494,553
Technical Sentiment Signal: Sell
Current Market Cap: $3.3M
Find detailed analytics on RDHL stock on TipRanks’ Stock Analysis page.